Summary:
- The article discusses the results of a clinical trial for patritumab deruxtecan, a new drug for the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
- The trial showed that patritumab deruxtecan demonstrated a statistically significant improvement in progression-free survival compared to standard doublet chemotherapy.
- These findings suggest that patritumab deruxtecan could be a promising new treatment option for patients with this type of lung cancer, providing improved outcomes compared to current standard of care.